<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2023-01-09</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2892</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NOTES FROM PRACTICE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ ОПЫТ</subject></subj-group></article-categories><title-group><article-title>Inflammatory Activity in Patients with Obstructive and Non-obstructive  Coronary Artery Disease</article-title><trans-title-group xml:lang="ru"><trans-title>Активность воспаления у больных c ишемической болезнью сердца и необструктивным поражением коронарных артерий</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0113-8768</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пахтусов</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Pakhtusov</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пахтусов Николай Николаевич.</p><p>Москва</p></bio><bio xml:lang="en"><p>Nikolay N. Pakhtusov.</p><p>Moscow</p></bio><email xlink:type="simple">pakhtusovnn@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9744-9183</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юсупова</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Yusupova</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юсупова Альфия Оскаровна.</p><p>Москва</p></bio><bio xml:lang="en"><p>Alfia O. Yusupova.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3391-0193</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лишута</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Lishuta</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лишута Алексей Сергеевич.</p><p>Москва</p></bio><bio xml:lang="en"><p>Alexey S. Lishuta.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1172-1116</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Слепова</surname><given-names>О. A.</given-names></name><name name-style="western" xml:lang="en"><surname>Slepova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Слепова Ольга Александровна.</p><p>Москва</p></bio><bio xml:lang="en"><p>Olga A. Slepova.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6675-7557</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Привалова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Privalova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Привалова Елена Витальевна.</p><p>Москва</p></bio><bio xml:lang="en"><p>Elena V. Privalova.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3014-6129</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беленков</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Belenkov</surname><given-names>Yu. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Беленков Юрий Никитич.</p><p>Москва</p></bio><bio xml:lang="en"><p>Yuri N. Belenkov.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>07</day><month>03</month><year>2023</year></pub-date><volume>19</volume><issue>1</issue><fpage>26</fpage><lpage>33</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Pakhtusov N.N., Yusupova A.O., Lishuta A.S., Slepova O.A., Privalova E.V., Belenkov Y.N., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Пахтусов Н.Н., Юсупова А.О., Лишута А.С., Слепова О.A., Привалова Е.В., Беленков Ю.Н.</copyright-holder><copyright-holder xml:lang="en">Pakhtusov N.N., Yusupova A.O., Lishuta A.S., Slepova O.A., Privalova E.V., Belenkov Y.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2892">https://www.rpcardio.online/jour/article/view/2892</self-uri><abstract><sec><title>Aim</title><p>Aim. To study the levels of pro-inflammatory biomarkers  in patients with obstructive  and non-obstructive coronary  artery disease (CAD), to identify possible differences  for diagnosing the degree of coronary  obstruction.</p></sec><sec><title>Material and methods</title><p>Material and methods. The observational  study included two groups of patients: with non-obstructive (main group,  coronary artery stenosis &lt;50%; n=30) and obstructive  (comparison group,  hemodynamically significant  coronary  artery stenosis according to the results of coronary  angiography; n=30) CAD.  The levels of interleukin-1β (IL-1β) and interleukin 6 (IL-6) were measured in plasma using enzyme  immunoassay.</p></sec><sec><title>Results</title><p>Results. IL-6  levels were significantly higher in patients with obstructive  CAD  (p=0.006) than in patients with non-obstructive CAD.  There were no significant  differences  in the level of IL-1β in both groups  (p=0.482). When  constructing the ROC  curve,  the threshold  value of IL-6  was  26.060 pg/ml. At the level of IL-6  less than this value, CAD  was diagnosed with hemodynamically insignificant stenoses of the coronary  arteries.</p></sec><sec><title>Conclusion</title><p>Conclusion. The results of this study confirm that in patients with different types of coronary  artery lesions, there are differences  in the activity of the inflammation process in the arterial wall. IL-6  was higher in the obstructive  lesion group,  and IL-1β levels did not differ between groups.  Thus, it can be assumed  that hemodynamically significant  obstruction  of the coronary  arteries develops  as a result of highly  active inflammation of the vascular wall. Given the presence of a proven biological  basis and the available data on the effectiveness of monoclonal antibodies to IL-1β, one cannot exclude their possible benefit in a cohort of patients with CAD  and hemodynamically insignificant stenoses.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Изучить уровни провоспалительных биомаркеров у пациентов с ишемической болезнью сердца (ИБС) и гемодинамически незначимыми стенозами  коронарных артерий  (КА), выявить возможные  различия для диагностики степени обструкции коронарного русла.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В обсервационное исследование были включены две группы пациентов: с необструктивной (основная группа, стеноз КА&lt;50%; n=30) и обструктивной (группа сравнения, гемодинамически значимый  стеноз КА по результатам коронарографии; n=30) ИБС. Уровни  интерлейкина-1β (ИЛ-1β) и интерлейкина 6 (ИЛ-6) измеряли  в плазме крови с помощью  иммуноферментного анализа.</p></sec><sec><title>Результаты</title><p>Результаты. Уровень  ИЛ-6 были  значимо  выше  у пациентов с обструктивной ИБС  (p=0,006), чем у пациентов с необструктивной ИБС. Значимых различий в уровне  ИЛ-1β в обеих  группах выявлено  не было  (p=0,482). При  построении ROC-кривой  пороговое значение ИЛ-6 составило 26,060  пг/мл. При  уровне  ИЛ-6 меньше  данной  величины диагностировалась ИБС  с гемодинамически незначимыми стенозами  КА.</p></sec><sec><title>Заключение</title><p>Заключение. Результаты данного исследования подтверждают, что у пациентов с различными вариантами поражения КА имеются различия в активности процесса  воспаления в артериальной стенке.  ИЛ-6 был  выше  в группе  с обструктивным поражением, а уровни  ИЛ-1β  не различались между группами. Таким образом можно предположить, что гемодинамически значимая обструкция КА развивается вследствие высокоактивного воспаления сосудистой стенки. Учитывая наличие доказанной биологической основы и имеющихся данных эффективности моноклональных антител к ИЛ-1β, нельзя исключить  их возможную пользу и у когорты  пациентов с ИБС и гемодинамически незначимыми стенозами.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>необструктивная ишемическая болезнь сердца</kwd><kwd>интерлейкин 1β</kwd><kwd>интерлейкин 6</kwd><kwd>воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-obstructive coronary  artery disease</kwd><kwd>interleukin 1β</kwd><kwd>interleukin 6</kwd><kwd>inflammation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено  при финансовой поддержке  Российского научного фонда в виде  научного проекта  № 22-15-00424, научного гранта «Роль активации сигнального каскада WNT, процессов его эпигенетической регуляции и иммуноопосредованного воспаления в прогрессировании атеросклероза и возможности влияния  на него методом терапевтического неоангиогенеза у пациентов со стабильной  ишемической болезнью сердца».</funding-statement><funding-statement xml:lang="en">The study was financially  supported  by the Russian Science Foundation in the form of scientific project No. 22-15-00424, scientific grant "The role of activation of the WNT signaling cascade, the processes of its epigenetic regulation and immune-mediated inflammation in the progression of atherosclerosis  and the possibility of influencing it by therapeutic neoangiogenesis in patients with stable ischemic heart disease".</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153-e639. DOI:10.1161/CIR.0000000000001052.</mixed-citation><mixed-citation xml:lang="en">Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153-e639. DOI:10.1161/CIR.0000000000001052.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Payab M, Abedi M, Foroughi Heravani N et al. Brown adipose tissue transplantation as a novel alternative to obesity treatment: a systematic review. Int J Obes (London). 2021;45(1):109-21. DOI:10.1038/s41366-020-0616-5.</mixed-citation><mixed-citation xml:lang="en">Payab M, Abedi M, Foroughi Heravani N et al. Brown adipose tissue transplantation as a novel alternative to obesity treatment: a systematic review. Int J Obes (London). 2021;45(1):109-21. DOI:10.1038/s41366-020-0616-5.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Liu C, Han D, Liang P, Li Y, Cao F. The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease. Front Cell Dev Biol. 2021;9:636136. DOI:10.3389/fcell.2021.636136.</mixed-citation><mixed-citation xml:lang="en">Liu C, Han D, Liang P, Li Y, Cao F. The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease. Front Cell Dev Biol. 2021;9:636136. DOI:10.3389/fcell.2021.636136.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Müller P, Lemcke H, David R. Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and Improvement Strategies. Cell Physiol Biochem. 2018;48(6):2607-55. DOI:10.1159/000492704.</mixed-citation><mixed-citation xml:lang="en">Müller P, Lemcke H, David R. Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and Improvement Strategies. Cell Physiol Biochem. 2018;48(6):2607-55. DOI:10.1159/000492704.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chacko L, P Howard J, Rajkumar C, et al. Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes. 2020;13(2):e006363. DOI:10.1161/CIRCOUTCOMES.119.006363.</mixed-citation><mixed-citation xml:lang="en">Chacko L, P Howard J, Rajkumar C, et al. Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes. 2020;13(2):e006363. DOI:10.1161/CIRCOUTCOMES.119.006363.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589-610. DOI:10.1038/s41573-021-00198-1.</mixed-citation><mixed-citation xml:lang="en">Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589-610. DOI:10.1038/s41573-021-00198-1.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cochain C, Zernecke A. Macrophages in vascular inflammation and atherosclerosis. Pflugers Arch. 2017;469(3-4):485-99. DOI:10.1007/s00424-017-1941-y.</mixed-citation><mixed-citation xml:lang="en">Cochain C, Zernecke A. Macrophages in vascular inflammation and atherosclerosis. Pflugers Arch. 2017;469(3-4):485-99. DOI:10.1007/s00424-017-1941-y.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095-147. PMID:8630372.</mixed-citation><mixed-citation xml:lang="en">Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095-147. PMID:8630372.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">IL6R Genetics Consortium Emerging Risk Factors Collaboration; Sarwar N, Butterworth AS, Freitag DFet al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205-13. DOI:10.1016/S0140-6736(11)61931-4.</mixed-citation><mixed-citation xml:lang="en">IL6R Genetics Consortium Emerging Risk Factors Collaboration; Sarwar N, Butterworth AS, Freitag DFet al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205-13. DOI:10.1016/S0140-6736(11)61931-4.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium; Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214-24. DOI:10.1016/S0140-6736(12)60110-X.</mixed-citation><mixed-citation xml:lang="en">Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium; Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214-24. DOI:10.1016/S0140-6736(12)60110-X.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-10. DOI:10.1016/j.jacc.2012.10.027.</mixed-citation><mixed-citation xml:lang="en">Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-10. DOI:10.1016/j.jacc.2012.10.027.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. DOI:10.1056/NEJMoa1707914.</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. DOI:10.1056/NEJMoa1707914.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Radico F, Zimarino M, Fulgenzi F, et al. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. Eur Heart J. 2018;39(23):2135-46. DOI 10.1093/eurheartj/ehy185.</mixed-citation><mixed-citation xml:lang="en">Radico F, Zimarino M, Fulgenzi F, et al. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. Eur Heart J. 2018;39(23):2135-46. DOI 10.1093/eurheartj/ehy185.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jespersen L, Abildstrom SZ, Hvelplund A, et al. Burden of hospital admission and repeat angiography in angina pectoris patients with and without coronary artery disease: a registry-based cohort study. PLoS One. 2014;9(4):e93170. DOI:10.1371/journal.pone.0093170.</mixed-citation><mixed-citation xml:lang="en">Jespersen L, Abildstrom SZ, Hvelplund A, et al. Burden of hospital admission and repeat angiography in angina pectoris patients with and without coronary artery disease: a registry-based cohort study. PLoS One. 2014;9(4):e93170. DOI:10.1371/journal.pone.0093170.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Shaw LJ, Merz CN, Pepine CJ, et al.; Women's Ischemia Syndrome Evaluation (WISE) Investigators. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. Circulation. 2006;114(9):894-904. DOI:10.1161/CIRCULATIONAHA.105.609990.</mixed-citation><mixed-citation xml:lang="en">Shaw LJ, Merz CN, Pepine CJ, et al.; Women's Ischemia Syndrome Evaluation (WISE) Investigators. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. Circulation. 2006;114(9):894-904. DOI:10.1161/CIRCULATIONAHA.105.609990.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149-60. DOI:10.3758/BRM.41.4.1149.</mixed-citation><mixed-citation xml:lang="en">Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149-60. DOI:10.3758/BRM.41.4.1149.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammad-Rezaei M, Ahmadi R, Rafiei A, et al. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α. Mol Biol Rep. 2021;48(5):4263-71. DOI:10.1007/s11033-021-06441-7.</mixed-citation><mixed-citation xml:lang="en">Mohammad-Rezaei M, Ahmadi R, Rafiei A, et al. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α. Mol Biol Rep. 2021;48(5):4263-71. DOI:10.1007/s11033-021-06441-7.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ma W, Shen D, Liu J, et al. Statin Function as an Anti-inflammation Therapy for Depression in Patients With Coronary Artery Disease by Downregulating Interleukin-1β. J Cardiovasc Pharmacol. 2016;67(2):129-35. DOI:10.1097/FJC.0000000000000323.</mixed-citation><mixed-citation xml:lang="en">Ma W, Shen D, Liu J, et al. Statin Function as an Anti-inflammation Therapy for Depression in Patients With Coronary Artery Disease by Downregulating Interleukin-1β. J Cardiovasc Pharmacol. 2016;67(2):129-35. DOI:10.1097/FJC.0000000000000323.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Benjamin EJ, Muntner P, Alonso A, Virani SS, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. DOI:10.1161/CIR.0000000000000659.</mixed-citation><mixed-citation xml:lang="en">Benjamin EJ, Muntner P, Alonso A, Virani SS, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. DOI:10.1161/CIR.0000000000000659.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Koenig W. Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era. Eur Cardiol. 2017;12(2):89-91. DOI:10.15420/ecr.2017:18:1.</mixed-citation><mixed-citation xml:lang="en">Koenig W. Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era. Eur Cardiol. 2017;12(2):89-91. DOI:10.15420/ecr.2017:18:1.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Musher DM, Abers MS, Corrales-Medina VF. Acute Infection and Myocardial Infarction. N Engl J Med. 2019;380(2):171-6. DOI:10.1056/NEJMra1808137.</mixed-citation><mixed-citation xml:lang="en">Musher DM, Abers MS, Corrales-Medina VF. Acute Infection and Myocardial Infarction. N Engl J Med. 2019;380(2):171-6. DOI:10.1056/NEJMra1808137.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664.</mixed-citation><mixed-citation xml:lang="en">Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215-22. DOI:10.1160/TH09-05-0297.</mixed-citation><mixed-citation xml:lang="en">Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215-22. DOI:10.1160/TH09-05-0297.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Schieffer B, Selle T, Hilfiker A, et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004;110(22):3493-500. DOI:10.1161/01.CIR.0000148135.08582.97.</mixed-citation><mixed-citation xml:lang="en">Schieffer B, Selle T, Hilfiker A, et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004;110(22):3493-500. DOI:10.1161/01.CIR.0000148135.08582.97.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Niu W, Liu Y, Qi Y, et al. Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol. 2012;157(2):243-52. DOI:10.1016/j.ijcard.2011.12.098.</mixed-citation><mixed-citation xml:lang="en">Niu W, Liu Y, Qi Y, et al. Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol. 2012;157(2):243-52. DOI:10.1016/j.ijcard.2011.12.098.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Held C, White HD, Stewart RAH, et al.; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):e005077. DOI:10.1161/JAHA.116.005077.</mixed-citation><mixed-citation xml:lang="en">Held C, White HD, Stewart RAH, et al.; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):e005077. DOI:10.1161/JAHA.116.005077.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Rai H, Colleran R, Cassese S, et al. Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis. Inflamm Res. 2021;70(10-12):1075-87. DOI:10.1007/s00011-021-01505-7.</mixed-citation><mixed-citation xml:lang="en">Rai H, Colleran R, Cassese S, et al. Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis. Inflamm Res. 2021;70(10-12):1075-87. DOI:10.1007/s00011-021-01505-7.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammad-Rezaei M, Ahmadi R, Rafiei A, et al. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α. Mol Biol Rep. 2021;48(5):4263-71. DOI:10.1007/s11033-021-06441-7.</mixed-citation><mixed-citation xml:lang="en">Mohammad-Rezaei M, Ahmadi R, Rafiei A, et al. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α. Mol Biol Rep. 2021;48(5):4263-71. DOI:10.1007/s11033-021-06441-7.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Enayati S, Seifirad S, Amiri P, et al. Interleukin-1 beta, interferon-gamma, and tumor necrosis factor-alpha gene expression in peripheral blood mononuclear cells of patients with coronary artery disease. ARYA Atheroscler. 2015;11(5):267-74.</mixed-citation><mixed-citation xml:lang="en">Enayati S, Seifirad S, Amiri P, et al. Interleukin-1 beta, interferon-gamma, and tumor necrosis factor-alpha gene expression in peripheral blood mononuclear cells of patients with coronary artery disease. ARYA Atheroscler. 2015;11(5):267-74.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
